Comment on: Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia

Pediatr Blood Cancer. 2021 Nov;68(11):e29294. doi: 10.1002/pbc.29294. Epub 2021 Aug 13.

Authors

Mariana Bohns Michalowski^{1

2}, Daiane Keller Cecconello^{1

2}

Affiliations

¹ Graduate Program in Child and Adolescent Health, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
² Translational Pediatrics Laboratory, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.

PMID: 34390162
DOI: 10.1002/pbc.29294

No abstract available

Publication types

Letter

MeSH terms

Acute Disease
Antineoplastic Agents* / therapeutic use
Asparaginase* / therapeutic use
Drugs, Generic* / therapeutic use
Escherichia coli / enzymology
Humans
India
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Therapeutic Equivalency

Substances

Antineoplastic Agents
Drugs, Generic
Asparaginase